US District Court

Roche Hemlibra patent appeal, Baxalta hemophilia A patent invalid, Hemlibra vs Baxalta hemophilia drug, Roche Genentech Hemlibra sales, Baxalta Takeda patent infringement lawsuit, Hemlibra patent enablement requirement, Roche Hemlibra adverse events,

Roche wins patent appeal over Hemlibra, its hemophilia A drug, against Takeda’s Baxalta

Anika Sharma

In a patent dispute revolving around two competing hemophilia medications, Roche’s Genentech unit has achieved its second consecutive victory. Following ...

Novartis to Appeal Court Decision on Entresto Combination Patent; Confirms 2023 Guidance and Mid-Term Outlook. Pharmtales - Latest Pharma News and Insights

Novartis to Appeal Court Decision on Entresto Combination Patent; Confirms 2023 Guidance and Mid-Term Outlook

SG Tylor

Source: Novartis On July 7, 2023, Novartis received a negative decision from the US District Court regarding the validity of ...